Previous 10 | Next 10 |
2023-10-16 17:25:11 ET Gainers: Y-mAbs Therapeutics ( YMAB ) +6% . CrossFirst Bankshares ( CFB ) +4% . Iris Energy ( IREN ) +4% . Vir Biotechnology ( VIR ) +3% . Service Properties Trust ( SVC ) +3% . Losers: NetSco...
2023-10-16 13:36:37 ET Gainers: Tempest Therapeutics ( TPST ) +98% . Momentus ( MNTS ) +51% . PCTEL ( PCTI ) +47% . Almacenes Exito ( EXTO ) +33% . Mereo Biopharma Group Plc ( MREO ) +30% . Rani Therapeutics Holdings ( RANI...
2023-10-16 09:09:21 ET DENVER, Colo., Oct 16, 2023 ( www.247marketnews.com )- Ambrx Biopharma, Inc. (NASDAQ: AMAM) stated, this morning, that it published two abstracts detailing updated safety and efficacy data from the ongoing Phase 1/2 trial, APEX-01 (NCT04662580), evaluating ARX517 ...
Newly published abstract regarding dose escalation patients provides key updates including: ≥50% PSA reduction observed across putative therapeutic dose levels ≥2.0 mg/kg – 3 of 3 in Cohort 6 (2.0 mg/kg), 2 of 3 in Cohort 7 (2.4 mg/kg) and 2 of 3 in Cohort 8 (2.88 m...
2023-10-13 15:00:54 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that it will host an in-person key opinion leader (KOL) event during the European Society for Medical Oncology (ESMO) Congress 2023. The event will take place...
2023-09-21 19:47:58 ET Shares of Ambrx Biopharma (NASDAQ: AMAM) were up more than 27% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence . The clinical-stage biotech closed last week at $10.25, then rose as high as $12.20 on...
2023-09-20 11:41:55 ET Ambrx Biopharma ( NASDAQ: AMAM ) disclosed on Sept. 19 that Cormorant Asset Management purchased 2.15M shares in the company from a period between Sept.15 to 18. The shares were purchased at a price between $9.05- $9.24. Cormorant Asset Manageme...
Morgan Stanley Fireside Chat Replay Now Available SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O’Connor, Chief Executive Officer and President of Ambrx, will participate in ...
2023-09-15 13:11:06 ET Gainers: MSP Recovery ( LIFW ) +199% . AERWINS Technologies ( AWIN ) +104% . AgriFORCE Growing Systems Ltd. ( AGRI ) +40% . RayzeBio ( RYZB ) +37% . Novonix Limited ( NVX ) +31% . Greenland Technologies...
News, Short Squeeze, Breakout and More Instantly...
Ambrx Biopharma Inc. American Depositary Shares (each representing seven) Company Name:
AMAM Stock Symbol:
NYSE Market:
Ambrx Biopharma Inc. American Depositary Shares (each representing seven) Website:
Shandong Weigao Group Medical Polymer Co. Ltd. - Class H (SHWGF) is expected to report for Q4 2023 Country Garden Holdings Co., Ltd. ADR (CTRYY) is expected to report for Q4 2023 Mondi Plc ADR (New) (MONDY) is expected to report for Q4 2023 Telecom Italia S.p.A. ADR - Preference Share...
Ambrx Biopharma Inc. (AMAM) is expected to report $-0.41 for Q4 2023
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Spe...